No price history available.
Key financial summary
Financials in KRW| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | KRWm | 30,076,510 | 42,654,722 | 50,983,251 | 55,249,785 | 48,916,104 | 45,932,167 | N/A | N/A |
| Operating profit | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | KRWm | 512,634 | 3,669,787 | 1,845,363 | 1,337,812 | -690,854 | -1,819,449 | N/A | N/A |
| EPS reported | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | KRWm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | KRW | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in KRW| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Established in Seoul, South Korea, in 1947, LG Chem, Ltd. is a global enterprise with diverse operations across petrochemicals, energy solutions, advanced materials, and life sciences. Its expansive reach covers South Korea, China, other Asian countries, the United States, Europe, and various international markets. Within its petrochemical segment, the company produces fundamental olefin products like ethylene, propylene, and butadiene, primarily sourced from naphtha. This division also yields an extensive array of synthetic resins and components, alongside aromatic petrochemicals such as benzene, polypropylene, bisphenol A, acrylonitrile butadiene styrene (ABS), engineered plastics (EP), polyvinyl chloride (PVC), plasticizers, acrylics, super absorbent polymers, and synthetic rubber. The energy solutions division specializes in manufacturing and supplying batteries for consumer electronics like mobile phones and laptops, electric vehicles, and large-scale energy storage systems. LG Chem's advanced materials business focuses on specialized products including polarizers, automotive components, glass substrates, OLED films and materials, and battery materials. It also provides reverse osmosis (RO) membranes, semiconductor materials, and display materials, such as LCD photoresists. In life sciences, the company's offerings include human growth hormones like Eutropin, diabetes treatments such as Zemiglo, bovine somatotropins (Boostin), vaccines, and hyaluronic acid dermal fillers (e.g., YVORIE). Additionally, they develop fine chemical products, exemplified by the PYANCHOR herbicide for rice farming. Beyond these core areas, LG Chem's activities encompass agricultural solutions, including crop protection products, seeds, fertilizers, and pesticides, alongside pharmaceutical research and facility management services. The company also manufactures and markets adhesives and electronic parts, distributes pharmaceutical products and water processing membranes, engages in agricultural pesticide licensing, and makes strategic investments in venture companies.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
LG Chem, Ltd. (051910.KS)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Established in Seoul, South Korea, in 1947, LG Chem, Ltd. is a global enterprise with diverse operations across petrochemicals, energy solutions, advanced materials, and life sciences. Its expansive reach covers South Korea, China, other Asian countries, the United States, Europe, and various international markets. Within its petrochemical segment, the company produces fundamental olefin products like ethylene, propylene, and butadiene, primarily sourced from naphtha. This division also yields an extensive array of synthetic resins and components, alongside aromatic petrochemicals such as benzene, polypropylene, bisphenol A, acrylonitrile butadiene styrene (ABS), engineered plastics (EP), polyvinyl chloride (PVC), plasticizers, acrylics, super absorbent polymers, and synthetic rubber. The energy solutions division specializes in manufacturing and supplying batteries for consumer electronics like mobile phones and laptops, electric vehicles, and large-scale energy storage systems. LG Chem's advanced materials business focuses on specialized products including polarizers, automotive components, glass substrates, OLED films and materials, and battery materials. It also provides reverse osmosis (RO) membranes, semiconductor materials, and display materials, such as LCD photoresists. In life sciences, the company's offerings include human growth hormones like Eutropin, diabetes treatments such as Zemiglo, bovine somatotropins (Boostin), vaccines, and hyaluronic acid dermal fillers (e.g., YVORIE). Additionally, they develop fine chemical products, exemplified by the PYANCHOR herbicide for rice farming. Beyond these core areas, LG Chem's activities encompass agricultural solutions, including crop protection products, seeds, fertilizers, and pesticides, alongside pharmaceutical research and facility management services. The company also manufactures and markets adhesives and electronic parts, distributes pharmaceutical products and water processing membranes, engages in agricultural pesticide licensing, and makes strategic investments in venture companies.
